Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease

D. Kampel Stolnicki, MD, Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa de Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil.
L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
C.E. Gollins, MBChB, Dermatology Department, Royal United Hospitals Bath NHS Foundation Trust, and Department of Life Sciences, University of Bath, Bath, UK.
S. Koppikar, MD, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada.
L.M. Perez-Chada, MD, MMSc, Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
L. Puig, MD, PhD, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, and Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain.
A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
A. Deodhar, MD, Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregan, USA.
C. Ritchlin, MD, MPH, Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA.
S.T. Hwang, MD, PhD, Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA.
C. Goldenstein-Schainberg, MD, PhD, Disciplina de Reumatologia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

As part of the supplement series GRAPPA 2023, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.
LCC is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.
LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; worked as a paid consultant for AbbVie, Amgen, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer, and UCB; received speaker fees from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer, and UCB. LMPC has received grant funding from GRAPPA. LP has received consulting, advisory boards, and/or speaker's fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, J&J Innovative Medicine, Leo, Lilly, Novartis, Pfizer, Sandoz, Samsung- Bioepis, Sanofi, and UCB. AO has been a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Kopa/Twill Health, Lilly, Novartis, Pfizer, UCB, and Takeda; and received grant funding from AbbVie (to Penn), Novartis (to Penn), Pfizer (to Penn), Amgen (to Forward/NDB), NIH/NIAMS, National Psoriasis Foundation, Rheumatology Research Foundation, and Forward Databank. AD has received consulting fees or been on the advisory boards for AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer, UCB; and received research grants from BMS, Celgene, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, and UCB. CGS has been on the speakers' bureau and been a consultant for AbbVie, Janssen, and Novartis. The remaining authors declare no conflicts of interest relevant to this article.
This paper does not require institutional review board approval.
Accepted for publication June 24, 2024.

Address correspondence to Dr. C. Goldenstein-Schainberg, Disciplina de Reumatologia, LIM17, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, Sao Paulo - SP, 05403-010, Brazil. Email: claudia.schainberg@hc.fm.usp.br.